Qiagen said this week that it has launched the first assays based on its QIAplex PCR multiplex technology, which enables the detection of multiple molecular targets in one test.
The ResPlex I Panel, ResPlex II Panel, and StaphPlex Panel allow parallel detection of more than ten bacterial and viral targets in a single reaction, the company said.
The ResPlex I Panel detects respiratory bacterial DNA, including DNA specific for Legionella pneumophila, Chlamydia pneumoniae, and Mycoplasma pneumoniae. ResPlex II detects respiratory viral RNA from influenza and parainfluenza viruses, RSV, metapneumovirus, and rhinoviruses. The StaphPlex Panel identifies methicillin-resistant Staphylococcus aureus DNA.
All three panels are available for research use only.